Overview

Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Status:
Not yet recruiting
Trial end date:
2024-09-13
Target enrollment:
Participant gender:
Summary
A study to evaluate the safety, efficacy and tolerability of remibrutinib at three doses versus placebo in adult participants who have a confirmed allergy to peanuts. The efficacy will be measured by the ability of participants to tolerate increasing doses of peanut protein during an oral food challenge after 1 month of study treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals